[
  {
    "ts": null,
    "headline": "Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider",
    "summary": "Pfizer (PFE) reached $26.5 at the closing of the latest trading day, reflecting a +2.4% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=a57b3053571111ebb3cd2d29fc4c310843e27542fcec28cdd0d936fb5832665b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769553904,
      "headline": "Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider",
      "id": 138277144,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) reached $26.5 at the closing of the latest trading day, reflecting a +2.4% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=a57b3053571111ebb3cd2d29fc4c310843e27542fcec28cdd0d936fb5832665b"
    }
  },
  {
    "ts": null,
    "headline": "Clinical Data Management System Market Report 2026: Trends, Strategies and Investments | Astute Analytica",
    "summary": "Growth is being driven by the increasing complexity of clinical trials, the rising volume of trial data, and the urgent need for streamlined, accurate, and secure data handling solutions. Pharmaceutical giants, contract research organizations, and academic institutions are increasingly adopting advanced CDMS platforms.Chicago, Jan. 27, 2026 (GLOBE NEWSWIRE) -- The global clinical data management system market was valued at 4.08 billion in 2024 and is expected to reach US$ 10.35 billion by 2033,",
    "url": "https://finnhub.io/api/news?id=d0e820d5724e104efc863a659586c9410e015a351bfbb9af5263c205eb0f0a62",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769538840,
      "headline": "Clinical Data Management System Market Report 2026: Trends, Strategies and Investments | Astute Analytica",
      "id": 138274071,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Growth is being driven by the increasing complexity of clinical trials, the rising volume of trial data, and the urgent need for streamlined, accurate, and secure data handling solutions. Pharmaceutical giants, contract research organizations, and academic institutions are increasingly adopting advanced CDMS platforms.Chicago, Jan. 27, 2026 (GLOBE NEWSWIRE) -- The global clinical data management system market was valued at 4.08 billion in 2024 and is expected to reach US$ 10.35 billion by 2033,",
      "url": "https://finnhub.io/api/news?id=d0e820d5724e104efc863a659586c9410e015a351bfbb9af5263c205eb0f0a62"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=bf60e3ea18b590f8c51e166254a12f2196b2337e83efc6cecbef661d99f608db",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769531760,
      "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "id": 138285131,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=bf60e3ea18b590f8c51e166254a12f2196b2337e83efc6cecbef661d99f608db"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer, Merck, CoreWeave, Zoom: Top Analyst Calls",
    "summary": "Yahoo Finance Senior Reporter Brooke DiPalma keeps track of several Wall Street analyst calls on top trending stocks, including calls around shares of Pfizer (PFE), Merck (MRK), CoreWeave (CRWV), and Zoom Communications (ZM).To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=3c021d39f2ac0cdf89bf17d1d9b9d2259519371cc542bb4e1652b817b840653e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769528721,
      "headline": "Pfizer, Merck, CoreWeave, Zoom: Top Analyst Calls",
      "id": 138270994,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Yahoo Finance Senior Reporter Brooke DiPalma keeps track of several Wall Street analyst calls on top trending stocks, including calls around shares of Pfizer (PFE), Merck (MRK), CoreWeave (CRWV), and Zoom Communications (ZM).To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=3c021d39f2ac0cdf89bf17d1d9b9d2259519371cc542bb4e1652b817b840653e"
    }
  },
  {
    "ts": null,
    "headline": "Earnings Preview: Pfizer (PFE) Q4 Earnings Expected to Decline",
    "summary": "Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=999dda78bb751052cd2a1057b9c3f43e39f8c3004631ab7bd6e4559656611b7a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769526005,
      "headline": "Earnings Preview: Pfizer (PFE) Q4 Earnings Expected to Decline",
      "id": 138272555,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=999dda78bb751052cd2a1057b9c3f43e39f8c3004631ab7bd6e4559656611b7a"
    }
  },
  {
    "ts": null,
    "headline": "Melmark Appoints Two New Members to Board of Directors",
    "summary": "Dr. Howard Mayer Dr. Mayer recently joined Melmark's Board of Directors. Amanda Westphal Radcliffe Ms. Radcliffe recently joined Melmark's Board of Directors. Andover, MA, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Melmark, a nationally-recognized non-profit human services provider for individuals with autism and intellectual disabilities, has appointed Dr. Howard Mayer and Amanda Westphal Radcliffe to its Board of Directors. Dr. Mayer, formerly Executive Vice President and Head of Research and Developme",
    "url": "https://finnhub.io/api/news?id=72cb5d76725d4e642a70a8427478e5b4eeec725f6976627600e250dbc0ff342c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769524680,
      "headline": "Melmark Appoints Two New Members to Board of Directors",
      "id": 138271058,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Dr. Howard Mayer Dr. Mayer recently joined Melmark's Board of Directors. Amanda Westphal Radcliffe Ms. Radcliffe recently joined Melmark's Board of Directors. Andover, MA, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Melmark, a nationally-recognized non-profit human services provider for individuals with autism and intellectual disabilities, has appointed Dr. Howard Mayer and Amanda Westphal Radcliffe to its Board of Directors. Dr. Mayer, formerly Executive Vice President and Head of Research and Developme",
      "url": "https://finnhub.io/api/news?id=72cb5d76725d4e642a70a8427478e5b4eeec725f6976627600e250dbc0ff342c"
    }
  },
  {
    "ts": null,
    "headline": "Baseline Therapeutics Launches to Advance GLP-1RA Phase 3 Program in Alcohol Use Disorder",
    "summary": "SAN FRANCISCO, January 27, 2026--Baseline Therapeutics, Inc. (\"Baseline\"), a clinical-stage biotechnology company developing addiction therapeutics, today announced the launch of the company to advance a new generation of pharmacotherapies for substance use disorders.",
    "url": "https://finnhub.io/api/news?id=79524dd364c36d9b61273625954449c4320c08b572bf0e60223996f56370de5d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769519880,
      "headline": "Baseline Therapeutics Launches to Advance GLP-1RA Phase 3 Program in Alcohol Use Disorder",
      "id": 138270159,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "SAN FRANCISCO, January 27, 2026--Baseline Therapeutics, Inc. (\"Baseline\"), a clinical-stage biotechnology company developing addiction therapeutics, today announced the launch of the company to advance a new generation of pharmacotherapies for substance use disorders.",
      "url": "https://finnhub.io/api/news?id=79524dd364c36d9b61273625954449c4320c08b572bf0e60223996f56370de5d"
    }
  },
  {
    "ts": null,
    "headline": "These 4 Measures Indicate That Pfizer (NYSE:PFE) Is Using Debt Extensively",
    "summary": "David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...",
    "url": "https://finnhub.io/api/news?id=0b87691698499b6d7e0c3d25e5cbe52eeab67431c870885efbe339ce583b45ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769518822,
      "headline": "These 4 Measures Indicate That Pfizer (NYSE:PFE) Is Using Debt Extensively",
      "id": 138270160,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...",
      "url": "https://finnhub.io/api/news?id=0b87691698499b6d7e0c3d25e5cbe52eeab67431c870885efbe339ce583b45ed"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer’s CEO on leading after a moonshot—and making deals with Trump",
    "summary": "Also: All the news and watercooler chat from Fortune.",
    "url": "https://finnhub.io/api/news?id=4385a591ff7f3d88dee49e724f692aa12da1c27cbdfa87a48a493cfa3fe346f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769510300,
      "headline": "Pfizer’s CEO on leading after a moonshot—and making deals with Trump",
      "id": 138270161,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Also: All the news and watercooler chat from Fortune.",
      "url": "https://finnhub.io/api/news?id=4385a591ff7f3d88dee49e724f692aa12da1c27cbdfa87a48a493cfa3fe346f8"
    }
  },
  {
    "ts": null,
    "headline": "What Are Wall Street Analysts' Target Price for Pfizer Stock?",
    "summary": "Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook.",
    "url": "https://finnhub.io/api/news?id=8e15d2641b690b55be1488497e0d80437bcf5b009f84f954673c59a01c656775",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769509952,
      "headline": "What Are Wall Street Analysts' Target Price for Pfizer Stock?",
      "id": 138270162,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook.",
      "url": "https://finnhub.io/api/news?id=8e15d2641b690b55be1488497e0d80437bcf5b009f84f954673c59a01c656775"
    }
  },
  {
    "ts": null,
    "headline": "Roche Obesity Shot Helps Patients Lose Weight in Midstage Trial",
    "summary": "Roche  Holding said an experimental injection achieved positive results in a midstage clinical trial by helping patients shed weight, paving the way for the start of the company’s first late-stage obesity study.  Eli Lilly  and  Novo Nordisk’s  GLP-1 drugs currently dominate the obesity-drug market, but big drugmakers including Roche, Pfizer and Amgen, as well as smaller players, are trying to come up with new treatments to challenge them.  Roche is looking to establish an obesity franchise with several drug candidates under development that it aims to launch as standalone treatments or combined among them, with the goal of becoming a top three player in the market.",
    "url": "https://finnhub.io/api/news?id=8c298ef3b97a7e6659da510c7e0d97e5f8f37afa1b5eb7b32baef59a7516497e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769505000,
      "headline": "Roche Obesity Shot Helps Patients Lose Weight in Midstage Trial",
      "id": 138269287,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Roche  Holding said an experimental injection achieved positive results in a midstage clinical trial by helping patients shed weight, paving the way for the start of the company’s first late-stage obesity study.  Eli Lilly  and  Novo Nordisk’s  GLP-1 drugs currently dominate the obesity-drug market, but big drugmakers including Roche, Pfizer and Amgen, as well as smaller players, are trying to come up with new treatments to challenge them.  Roche is looking to establish an obesity franchise with several drug candidates under development that it aims to launch as standalone treatments or combined among them, with the goal of becoming a top three player in the market.",
      "url": "https://finnhub.io/api/news?id=8c298ef3b97a7e6659da510c7e0d97e5f8f37afa1b5eb7b32baef59a7516497e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance",
    "summary": "Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance",
    "url": "https://finnhub.io/api/news?id=1b46281afdf61f42a11f8be89c30b9dd07b91026049f61f9dca4e9e588b54b4f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769493725,
      "headline": "Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance",
      "id": 138269077,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=1b46281afdf61f42a11f8be89c30b9dd07b91026049f61f9dca4e9e588b54b4f"
    }
  }
]